Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2019, Article ID 4325946, 7 pages
Research Article

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

1Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
2University of Pavia, Ph.D. in Experimental Medicine, Pavia 27100, Italy
3Medical Physics Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
4Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Milan 20090, Italy
5Nuclear Medicine Research Department, Iason, Graz, Austria
6Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
7Scientific Direction, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
8Nuclear Medicine Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
9Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
10Translational Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy
11University of Pavia, Department of Internal Medicine, Pavia 27100, Italy

Correspondence should be addressed to E. Quaquarini; ti.ireguamsci@inirauqauq.acire

Received 7 December 2018; Accepted 19 February 2019; Published 26 March 2019

Academic Editor: Gaurav Malviya

Copyright © 2019 E. Quaquarini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and Aim. The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of 18F-fluorocholine (18F-FCH) positron emission tomography (PET) parameters in mCRPC. Materials and Methods. Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent 18F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment 18F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUVmax, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body 18F-FCH PET indices were performed, and was considered as significant. Results. Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and 18F-FCH PET parameters were defined probably due to the small sample size. Conclusions. Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of 18F-FCH PET/CT imaging in clinical decision-making.